Acenocoumarol
Adverse Effect: Increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent Amlodipine and Acenocoumarol should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Amiodarone
Adverse Effect: Atrioventricular block and slowing of sinus rate Clinical Management: Concurrent use of amiodarone and Amlodipine should be avoided in patients with sick sinus syndrome or partial AV (atrioventricular) block.
Atenolol
Adverse Effect: Hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Betaxolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Bisoprolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Carvedilol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Celecoxib
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Celiprolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Esmolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Fluconazole
Adverse Effect: Increased amlodipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema) Clinical Management: Observe for development of toxicity associated with Amlodipine (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of the Amlodipine or withdrawing one of the agents.
Flurbiprofen
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ibuprofen
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ibuprofen Comb.
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Indomethacin
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Itraconazole
Adverse Effect: Increased amlodipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema) Clinical Management: Observe for development of toxicity associated with amlodipine (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of amlodipine or withdrawing one of the agents.
Ketoconazole
Adverse Effect: Increased Amlodipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema) Clinical Management: Observe for development of toxicity associated with the Amlodipine (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of the Amlodipine or withdrawing one of the agents.
Ketoprofen
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketorolac
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Labetalol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Levobunolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Mefenamic Acid
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Meloxicam
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Metoprolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Nabumetone
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Naproxen
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Nimesulide
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Oxprenolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Oxyphenbutazone
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Paracetamol
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Paracetamol Comb.
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenacetin
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenindione
Adverse Effect: an increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent Amlodipine and Phenindione should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Phenylbutazone
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Pindolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Piroxicam
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Propranolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Rifampicin
Adverse Effect: Decreased amlodipine efficacy
Tenoxicam
Adverse Effect: An increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Timolol
Adverse Effect: hypotension and/or bradycardia Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Warfarin
Adverse Effect: Increased risk of gastrointestinal hemorrhage Clinical Management: Patients who are receiving concurrent Amlodipine and Warfarin should be monitored for excessive bleeding, especially from the gastrointestinal tract. |